Status:
COMPLETED
Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Psoriasis
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Body mass index of 18.0 to 32.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
- Estimated glomerular filtration rate (eGFR) \> 80 mL/min/1.732 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula
Exclusion
- Any significant acute or chronic medical illness
- Current or recent (within 3 months of study drug administration) disease of the gut that, in the opinion of the Investigator or Medical Monitor, could impact upon the absorption of study drug
- Acute diarrhea, or constipation within 3 weeks prior to randomization
- Any major surgery within 4 weeks of randomization
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
January 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2019
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT03873415
Start Date
January 25 2019
End Date
May 1 2019
Last Update
November 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scintipharma
Lexington, Kentucky, United States, 40504